elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38199737-BD40AB8A-FA2A-4623-819C-AC638AAC52E1
Q38199737-BD40AB8A-FA2A-4623-819C-AC638AAC52E1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38199737-BD40AB8A-FA2A-4623-819C-AC638AAC52E1
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
P2860
Q38199737-BD40AB8A-FA2A-4623-819C-AC638AAC52E1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38199737-BD40AB8A-FA2A-4623-819C-AC638AAC52E1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ddea15a7f01fdda24844c62df8294894952f9953
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.